Source: PIB, PTI, The Hindu, The Indian Express, DD News, Lok Sabha Channel, All India Radio
Swedish-British drug giant AstraZeneca recently said it was moving an antibody combination developed for Covid-19 treatment into late-stage human trials.
- AZD7442, a similar class of the drug cocktail used to treat US President Donald Trump recently, is a combination of two long-acting monoclonal antibodies (LAAB). AstraZeneca developed it using its proprietary technology with the aim of preventing Covid-19 infection for a long duration.
- LAABs mimic natural antibodies, and a combination of LAABs could be “complementary” to vaccines as a prophylactic agent, according to AstraZeneca. This means it could either be used on people for whom a vaccine may not be appropriate or it could be given as added protection for those at high-risk.